Список литературы

Поставить закладку

Абдулкадыров А.М., Абрамов М.Л., Агарков М.В., Артеменко С.Н., Артюхина Е.А., Баранова Е.И., Басова В.А., Баутин А.Е., Бернгардт Э.Р., Бочкарев М.В., Буданова М.А., Вандер М.А., Васильева О.И., Васичкина Е.С., Вахрушев А.Д., Вербило С.Л., Власенко С.В., Выговский А.Б., Гарькина С.В., Гасымова Н.З. и др. Руководство по аритмологии. Санкт-Петербург, 2019
Алексеева Д.Ю., Попов С.В., Тихоненко В.М., Земсков И.А., Васичкина Е.С. Возможности многосуточного телемониторирования электрокардиограммы у спортсменов детско-юношеских школ с желудочковыми аритмиями. Педиатрия. Consilium Medicum. 2019. № 2. С. 58-62.
Ахмедова Э.Э. Многосуточное мониторирование ЭКГ с телеметрическим контролем у детей с гипертрофической кардиомиопатией. Российский педиатрический журнал. 2020. Т. 23. № 6. С. 391.
Березнева Н.А., Сорокина Т.Е., Аверьянова Н.С., Громыко О.Е., Арсеньева Е.Н., Кустова О.В., Вашакмадзе Н.Д., Басаргина Е.Н., Пинелис В.Г. Артериальное давление и полиморфизм генов ренин-ангиотензивной системы у детей с гипертрофичекой кардиомиопатией. Российский педиатрический журнал. 2012. № 6. С. 10-13.
Бокерия Л.А., Борисов К.В., Синёв А.Ф., Злочевская Е.В. Хирургическое лечение гипертрофической обструктивной кардиомиопатии у детей. Детские болезни сердца и сосудов. 2005. № 1. С. 23-29.
Бокерия Л.А., Бокерия О.Л., Берсенева М.И., Тетвадзе И.В., Маленков Д.А., Макаренко В.Н., Александрова С.И., Косарева Т.И. Результаты хирургической коррекции гипертрофической обструктивной кардиомипатии у детей методом миоэктомии из правого желудочка. Бюллетень НЦССХ им. А.Н. Бакулева РАМН. Сердечно-сосудистые заболевания. 2012. Т. 13. № S6. С. 9
Бокерия, Л.А. Экспрессия генов матриксной металлопротеиназы-1 (ММР-1), тканевого ингибитора матриксных металлопротеиназ-1 (TIMP-1), коллагена I и Ш типов в миокарде больных идиопатической гипертрофической кардиомиопатией / Бокерия Л.А., Гудкова А.Я., Созин C.Е. и др. // Бюлл. НЦ ССХ имени А Н Бакулева РАМН, 2005;6.(4):35–42.
Васичкина Е.С., Вершинина Т.Л., Ковальчук Т.С., Блинова Е.Н., Малкина Е.В., Первунина Т.М. Поражение сердечно-сосудистой системы при мукополисахаридозе I типа: клинические случаи. Вопросы современной педиатрии. 2019. Т. 18. № 5. С. 346-353.
Вершинина Т.Л., Первунина Т.М., Никитина И.Л. Гипертрофическая кардиомиопатия у детей – стратегия диагностики и леченияВ сборнике: Клиническая медицина - 2015. сборник материалов международной научной конференции, 2 сессия [Электронный ресурс]. под ред. Г.А. Батрак. 2015. С. 50-63.
Вершинина Т.Л., Фомичева Ю.В., Васичкина Е.С., Муравьев А.С., Чуркина А.И., Мельник О.В., Киселев А.М., Козырева А.А., Первунина Т.М., Костарева А.А. Особенности клинического фенотипа филаминовых кардиомиопатий с дебютом в раннем детском возрасте. Педиатрия. Журнал им. Г.Н. Сперанского. 2020. Т. 99. № 3. С. 88-95.
Габрусенко С.А. Клинико-гемодинамический статус и сердечные натрийуретические пептиды в плазме больных гипертрофической кардиомиопатией / С.А. Габрусенко, Ю.В. Сафрыгина, А.Г. Овчинников и др. // Кардиологический вестник (Бюллетень РКНПК). 2006; 2:25–31.
Голубина И.В., Хакимов Д.П., Кариева Ш.А. Достоверность ЭКГ амплитуд в ранней диагностике гипертрофической кардиомиопатии у детей. Проблемы современной науки и образования. 2019. № 1 (134). С. 89-93.
Грознова О.С., Леонтьева И.В., Полякова А.В. Современные методы обследования больных гипертрофической кардиомиопатией //Российский вестник перинатологии и педиатрии 2014. -том.59. -№.4-с. 23-27.
Грознова О.С., Новиков П.В. Ранняя диагностика поражения сердца при Х-сцепленной форме мышечной дистрофии Эмери-Дрейфуса у детей. Российский вестник перинатологии и педиатрии. 2011. Т. 56. № 1. С. 63-78.
Грознова О.С., Чечуро В.В. Лечение кардиомиопатий у больных прогрессирующими мышечными дистрофиями. Российский вестник перинатологии и педиатрии. 2011. Т. 56. № 2. С. 58-62
Дарий О.Ю., Александрова С.А., Юрпольская Л.А., Макаренко В.Н. Бюллетень НЦССХ им. А.Н. Бакулева РАМН. Визуализация структурных изменений миокарда левого желудочка у детей и подростков с гипертрофической кардиомиопатией методом МРТ. Сердечно-сосудистые заболевания. 2020. Т. 21. № S6. С. 187.
Дземешкевич, С.Л. Анатомические и морфологические признаки диффузногенерализованной формы гипертрофической кардиомиопатии / С. Л. Дземешкевич, Ю.В. Фролова, С.Ю. Ким и др. // Российский кардиологический журнал. 2015;5(121): 58–63.
Емельянчик Е.Ю., Никулина С.Ю., Красикова Е.Ю. Молекулярно-генетические аспекты диагностики гипертрофических кардиомиопатий у детей. Лечащий врач. 2015. № 11. С. 65.
Кактурский, Л.В. Внезапная смерть (клиническая морфология) / Кактурский Л.В. // М.: Медицина для всех. 2000. 126 с.
Клинические рекомендации ОССН-РКО РНМОТ Сердечная недостаточность: хроническая (ХСН) и острая декомпенсированная (ОДСН). Диагностика, профилактика, лечение. 2018.
Крылова, Н.С. Гипертрофическая кардиомиопатия и артериальная гипертензия: возможно ли сочетание? / Крылова Н.С., Хашиева Ф.М., Демкина А.Е. и др.// Сердце: журнал для практикующих врачей. 2015;14(3 (83)):164–169.
Лаптева Н.М., Скачкова М.А., Тарасенко Н.Ф., Карпова Е.Г., Сероштан С.П., Маркова С.В., Маркунина Е.В. О случае ранней диагностики болезни Помпе у ребенка с гипертрофической кардиомиопатией. В сборнике: Детская кардиология 2012. VII Всероссийский конгресс. 2012. С. 332-334.
Леонтьева И.В. Дифференциальная диагностика гипертрофической кардиомиопатии Российский вестник перинатологии и педиатрии 2017;62(3):20-31.
Леонтьева И.В., КовалевИ.А. Прогноз при гипертрофической кардиомиопаии у детей. // Педиатрия 2020. -№5. -с.11-16
Леонтьева И.В., Макарова В.В., Термосесов С.А. Синкопальные состояния у детей с гипертрофической кардиомиопатией. //Российский вестник перинатологии и педиатрии2014. -т.59. -№;6. -с:57-65.
Леонтьева И.В., Николаева Е.А.. Кардиомиопатии при врожденных нарушениях метаболизма у детей Российский вестник перинатологии и педиатрии 2016; №2. том61. - 26-31
Леонтьева И.В., Николаева Е.А. Митохондриальные кардиомиопатии Российский вестник перинатологии и педиатрии 2016;3 22-30
Леонтьева И.В., Царегородцев Д.А. Лизосом-ассциированная гипертрофическая кардиомиопатия (болезнь Данона) у двух сибсов. //Российский вестник перинатологии и педиатрии. 2015т.60№;4. -с 75-82
Линяева В.В., Леонтьева И.В., Павлов В.И. Сравнительный анализ процесса реполяризации на фоне дозированной физической нагрузки у детей с гипертрофией миокарда различного генеза. // Педиатрия:2013; том.92№:6. -с. 164-166.
Макарова В.А., Леонтьева И.В. Турбулентность ритма сердца у детей с гипертрофической кардиомиопатией как маркер электрической нестабильности миокарда. //Российский вестник перинатологии и педиатрии. 2014.-.59 №4. -с.- 64-68
Мельник О.В., Лоевец Т.С., Вершинина Т.Л., Гудкова А.Я., Фомичева Ю.В., Костарева А.А., Первунина Т.М., Васичкина Е.С. Синдром Барта в практике кардиолога. Российский кардиологический журнал. 2018. Т. 23. № 3. С. 54-59.
Мельник О.В., Малашичева А.Б., Фомичева Ю.В., Худяков А.А., Гудкова А.Я., Руденко Д.И., Симоненко М.А., Михайлов Е.Н., Лебедев Д.С., Васичкина Е.С., Первунина Т.М., Костарева А.А. Клинико-диагностические сложности при ламинопатиях. Российский кардиологический журнал. 2019. Т. 24. № 10. С. 72-77.
Национальные клинические рекомендации: трансплантация сердца и механическая поддержка кровообращения. 2016.
Попов С.В., Алексеева Д.Ю., Земсков И.А., Васичкина Е.С., Григорьев В.В. Нагрузочные пробы в диагностике нарушении ритма и проводимости у спортсменов детско-юношеских школ. Российский кардиологический журнал. 2020. Т. 25. № S2. С. 36.
Ревишвили, А.Ш. Клинические рекомендации по проведению электрофизиологических исследований, катетерной абляции и применению имплантируемых антиаритмических устройств /Ревишвили А.Ш., Шляхто Е.В., Попов С.В. и др. // Новая редакция – 2017. C. 701.
Сафрыгина Ю.В. Сердечные натрийуретические пептиды в плазме больных гипертрофической кардиомиопатией / Ю.В. Сафрыгина, С.А. Габрусенко, А.Г. Овчинников и др. // Кардиология;2007(5):50–57.
Селезнёв Д.М. Роль мутаций в гене тяжелой цепи сердечного b-миозина в российской популяции больных гипертрофической кардиомиопатией / Д.М. Селезнёв, С.А. Габрусенко, Е.В. Парфёнова и др.// Кардиология. 2005; 4:15–20.
Стрельцова, А.А. Фибрилляция предсердий при гипертрофической кардиомиопатии: современные аспекты эпидемиологии, факторов риска, патогенеза и фармакотерапии / Стрельцова А.А., Гудкова А.Я., Костарева А.А. // Consilium Medicum. 2018;20(5):34–39.
Туральчук М.В. Клинико-функциональные и генетические аспекты кардиомиопатий, ассоциированных с гипертрофическим и рестриктивным фенотипами у детей и взрослых. Автореферат диссертации на соискание ученой степени кандидата медицинских наук / Санкт-Петербургская государственная педиатрическая медицинская академия. Санкт-Петербург, 2011
Тихомирова Е.А. Критерии прогнозирования и исхода гипертрофической кардиомиопатии у детей. Автореферат диссертации на соискание ученой степени кандидата медицинских наук / Научный центр здоровья детей Российской академии медицинских наук. Москва, 2007
Царегородцев Д.А., Букия И.Р., Сулимов В.А., Леонтьева И.В., Макарова В.А. Турбулентность ритма сердца и микровольтная альтернация зубца Т у больных с гипертрофической кардиомиопатией. // Кардиология. -2013. -№ 9-С, 40-45.
Черных Н.Ю., Грознова О.С., Довгань М.И., Подольский В.А. Изменение деформации миокарда как ранний маркер миокардиальной дисфункции при гипертрофической кардиомиопатии у детей. Российский вестник перинатологии и педиатрии. 2016. Т. 61. № 5. С. 70-74.
Черных Н.Ю., Грознова О.С., Тарасова А.А., Шигабеев И.М. Биохимические маркеры ишемии, сердечной недостаточности и деформации миокарда у детей с гипертрофической кардиомиопатией. Педиатрия. Приложение к журналу Consilium Medicum. 2018. № 4. С. 80-84.
Черных Н.Ю., Тарасова А.А., Грознова О.С. Деформация миокарда и хроническая сердечная недостаточность у детей с гипертрофической кардиомиопатией. Российский вестник перинатологии и педиатрии. 2018. Т. 63. № 4. С. 201.
2013 ESC guidelines on cardiac pacing and cardiac resynchronization therapy: the task force on cardiac pacing and resynchronization therapy of the European Society of Cardiology (ESC) // Europace. 2013; 15(8):1070–1118.
2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) // European Journal of Heart Failure. 2016;18:891–975
2017 ESC/EACTS Guidelines for the management of valvular heart disease The Task Force for the Management of Valvular Heart Disease of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). // Eur Heart J. 2017;38:2739–2791.
2020 AHA/ACC Guideline for the Diagnosis and Treatment of Patients With Hypertrophic Cardiomyopathy: Executive Summary: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines Circulation. 2020 Dec 22;142(25):e533-e557. doi: 10.1161/CIR.0000000000000938.
Adabag AS. Spectrum and prognostic significance of arrhythmias on ambulatory Holter electrocardiogram in hypertrophic cardiomyopathy / Adabag A.S., Casey S.A., Kuskowski M.A., Maron BJ. // J Am Coll Cardiol. 2005;45:697–704.
Albano BB. Treating a structural heart disease using a non-structural approach: role of cardiac pacing in hypertrophic cardiomyopathy / Albano BB, Fadreguilan EC, Chua JM, Ho J, Medrano AB. // Cardiol Res. 2017;8(1)20–25.
Albers S, Meibohm B, Mir TS, Läer S. Population pharmacokinetics and dose simulation of carvedilol in pediatric patients with congestive heart failure. Br J Clin Pharmacol 2008; 65(4): 511-22.
Alexander PMA, Nugent AW, Daubeney PEF, et al; National Australian Childhood Cardiomyopathy Study. Long-term outcomes of hypertrophic cardiomyopathy diagnosed during childhood: results from a national population-based study. Circulation. 2018;138(1):29-36. doi:10.1161/CIRCULATIONAHA.117.028895
Alfares A.A. Results of clinical genetic testing of 2,912 probands with hypertrophic cardiomyopathy: Expanded panels offer limited additional sensitivity / Alfares AA, Kelly MA, McDermott G et al. // Genetics in medicine: official journal of the American College of Medical Genetics. 2015;17:880–888.
Arola A, Jokinen E, Ruuskanen O, et al. Epidemiology of idiopathic cardiomyopathies in children and adolescents. A nationwide study in Finland. American journal of epidemiology . 1997;146(5):385–393
An integrative translational approach to study heart failure with preserved ejection fraction: a position paper from the Working Group on Myocardial Function of the European Society of Cardiology //European Journal of Heart Failure.2018; 20; 216–227.
Arbustini E. The MOGE(S) classification for a phenotype-genotype nomenclature of cardiomyopathy: endorsed by the World Heart Federation./ Arbustini E, Narula N, Dec GW et al. //J Am Coll Cardiol. 2013; 62:2046–2072.
Augustine DX. Left Ventricular Hypertrophy in Athletes: Differentiating Physiology From Pathology / Augustine DX, Howard L. // Curr Treat Options Cardiovasc Med. 2018;20(12):96.
AСС/AHA/ESC 2006 guidelines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death. //J Am Coll Cardiol.2006;48(5):247–346.
ACC/AHA/HRS 2008 Guidelines for Device-Based Therapy of Cardiac Rhythm Abnormalities ACC, AHA, HRS 2008
Balaji S, DiLorenzo M, Fish F, et al. Impact of obesity on left ventricular thickness in children with hypertrophic cardiomyopathy. Pediatr Cardiol 2019; 40:1253–1257.
Bales ND, Johnson NM, Judge DP, Murphy AM. Comprehensive Versus Targeted Genetic Testing in Children with Hypertrophic Cardiomyopathy. Pediatr Cardiol. 2016 Jun;37(5):845-51. doi: 10.1007/s00246-016-1358-y.
Barcia G. Pitfalls in molecular diagnosis of Friedreich ataxia / Barcia G, Rachid M, Magen M et al. // Eur J Med Genet. 2018; 8:455–458.
Barrett MJ. Cardiac auscultation in sports medicine: strategies to improve clinical care / Barrett MJ, Ayub B, Martinez MW //Curr Sports Med Rep. 2012; 2:78–84.
Bharucha T., Lee K..J, Daubeney P.l. Nugent A. , Turner C. , Sholler G. Robertson T. , Justo R. ,Ramsay J , Carlin J. , Colan C. King I , Weintraub R., Davis A. Sudden death in childhood cardiomyopathy: Results from a long-term national population-based study. J Am Coll Cardiol 2015; 65(21): 2302–2310
Bennett MK. Evaluation of the role of endomyocardial biopsy in 851 patients with unexplained heart failure from 2000–2009. / Bennett MK, Gilotra NA, Harrington C et al. //Circ Heart Fail. 2013; 6:676–684.
Bettencourt M, Cader SA, Araujo DV, et al. Role of myocardial fibrosis in hypertrophic cardiomyopathy: a systemic review and up-dated meta-analysis of risk markers for sudden death. Arq Bras Cardo 2019; 112:281–289.
Bharucha T, Lee KJ, Daubeney PEF, et al. Sudden death in childhood cardiomyopathy: results from a long-term national population-based study. J Am Col Cardiol 2015; 65:2302–2310.
Biagini E. Prognostic implications of the Doppler restrictive filling pattern in hypertrophic cardiomyopathy / Biagini E, Spirito P, Rocchi G et al. // Am J Cardiol. 2009; 104:1727–1731.
Biagini E., Coccolo F., Ferlito M. Perugini E., Rocchi G., Bacchi-Reggiani L., Lofiego C., Boriani G., Prandstraller D, Picchio F.M., Branzi A., Rapezzi C. Dilated-hypokinetic evolution of hypertrophic cardiomyopathy: prevalence, incidence, risk factors and prognostic implications in pediatric and adult patients. J Am Coll Cardiol 2005; 46{8): 1543–1550
Binder J. Echocardiography-guided genetic testing in hypertrophic cardiomyopathy: septal morphological features predict the presence of myofilament mutations / Binder J, Ommen SR, Gersh BJ, Van Driest SL, Tajik AJ, Nishimura RA, Ackerman MJ. // Mayo Clin Proc. 2006; 81(4):59–67.
Bockstall K., Link M. A primer on arrhythmias in patients with hypertrophic Cardiomyopathy. Curr Cardiol Rep 2012; 14(5): 552-562
Bonow RO. Verapamil-induced improvement in left ventricular diastolic filling and increased exercise tolerance in patients with hypertrophic cardiomyopathy. Short- and long-term effects / Bonow RO, Dilsizian V, Rosing DR et al. // Circulation. 1985;72:853–864.
Bonow RO. The acute and chronic effects of verapamil on left ventricular function in patients with hypertrophic cardiomyopathy / Bonow RO, Rosing DR, Epstein SE. // Eur Heart J. 1983;4:57–65.
Bravo PE. Late gadolinium enhancement confined to the right ventricular insertion points in hypertrophic cardiomyopathy: an intermediate stage phenotype? / Bravo PE, Luo HC, Pozios I et al. // Eur Heart J Cardiovasc Imaging. 2016; 3:293–300.
Brignole M. 2013 ESC Guidelines on cardiac pacing and cardiac resynchronization therapy: the Task Force on cardiac pacing and resynchronization therapy of the European Society of Cardiology (ESC). Developed in collaboration with the European Heart Rhythm Association (EHRA) / Brignole M, Auricchio A, BaronEsquivias G et al. // Eur Heart J. 2013;34:2281–2329.
Brignole M. Indications for the use of diagnostic implantable and external ECG loop recorders / Brignole M, Vardas P, Hoffman E et al. //Europace. 2009; 11:671–687.
Brignole M., Moya A.., de Lange F.J., Deharo J.C., Elliott P.M., Fanciulli A., Fedorowski A., Furlan R., Kenny R.A., Martín A., Probst V., Reed M.J., Rice C.P., Sutton .R, Ungar A., van Dijk J.G;.2018 Guidelines for the diagnosis and management of syncope . Eur Heart J 2018; 39(21): 1883–194836
Burstein B. Atrial fibrosis: mechanisms and clinical relevance in atrial fibrillation. / Burstein B, Nattel S. // J Am Coll Cardiol. 2008;51;802–808.
Burton H. Heart to Heart: inherited cardiovascular conditions services — a needs assessment and service review / Burton H., Alberg C., Stewart A. // PHG Fundation, UK. 2009.
Camm AJ. 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association / Camm AJ, Lip GY, De Caterina R et al. // Eur Heart J. 2012;33:2719–2747.
Camm CF. Atrial fibrillation and anticoagulation in hypertrophic cardiomyopathy / Camm CF, Camm AJ. // Arrhythmia and Electrophysiology Review. 2017;6(2):63–68.
Cardim N. Role of multimodality cardiac imaging in the management of patients with hypertrophic cardiomyopathy: an expert consensus of the European Association of Cardiovascular Imaging Endorsed by the Saudi Heart Association / Cardim N, Galderisi M, Edvardsen T et al. // Eur Heart J Cardiovasc Imaging. 2015; 16(3):280.
Cardoso B, Gomes I, Loureiro P, Trigo C, Ferreira Pinto F. Clinical and genetic diagnosis of familial hypertrophic cardiomyopathy: Results in pediatric cardiology. Rev Port Cardiol. 2017 Mar; 36(3):155-165. Doi: 10.1016/j.repc.2016.09.009.
Cerqueira MD. Standardized myocardial segmentation and nomenclature for tomographic imaging of the heart. A statement for healthcare professionals from the Cardiac Imaging Committee of the Council on Clinical Cardiology of the American Heart Association. / Cerqueira MD, Weissman NJ, Dilsizian V et al. //Circulation. 2002; 105:539–542.
Charron P. Genetic counselling and testing in cardiomyopathies: a position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases / Charron P, Arad M, Arbustini E et al. // Eur Heart J. 2010;31:2715–2726.
Charron P. Danon’s disease as a cause of hypertrophic cardiomyopathy: a systematic survey / Charron P, Villard E, Sebillon P et al. // Heart. 2004; 90:842– 846.
Charron P. Accuracy of European diagnostic criteria for familial hypertrophic cardiomyopathy in a genotyped population. Int. J. / Charron P, Forissier JF, Amara ME et al. //Cardiol. 2003; 90:33–38.
Chaudhry-Waterman N., Cohen M.I. Newer risk assessment strategies in hypertrophic cardiomyopathy. Curr Opin Cardiol. 2021 Jan;36(1):80-88. doi: 10.1097/HCO.0000000000000804.
Coats CJ Genetic biomarkers in hypertrophic cardiomyopathy / Coats CJ, Elliott P.M. // Biomark. Med. 2013; 7:505–516.
Colan SD, Lipshultz SE, Lowe AM, et al. Epidemiology and cause-specific outcome of hypertrophic cardiomyopathy in children: findings from the Pediatric Cardiomyopathy Registry. Circulation. 2007;115(6):773–781
Colan S.D., R. Margossian. Hypertrophic Cardiomyopathy. Chapter 19 in Heart Failure in the Child and Young Adult. Copyright © 2018 Elsevier Inc. All rights reserved. http://dx.doi.org/10.1016/B978-0-12-802393-8.00019-3
Connolly SJ. Effect of clopidogrel added to aspirin in patients with atrial fibrillation / Connolly SJ, Pogue J, Hart RG et al. // N Engl J Med. 2009;353:2066–2078. 102.Cook A. Friedreich's ataxia: clinical features, pathogenesis and management. // Br Med Bull. 2017;24(1):19-30.
Corrado et al. Treatment of Arrhythmogenic Right Ventricular Cardiomyopathy/Dysplasia: An International Task Force Consensus Statement NA 2015
Coutu M. Cardiac transplantation for hypertrophic cardiomyopathy: a valid therapeutic option / Coutu M, Perrault LP, White M et al. // J Heart Lung Transplant. 2004; 23:413–417.
Covella M. Mechanism of progressive heart failure and significance of pulmonary hypertension in obstructive hypertrophic cardiomyopathy. / Covella M, Rowin EJ, Hill NS et al. // Circ Heart Fail. 2017; 10(4) e003689.
Christian S, Somerville M, Huculak C, Atallah J.Practice Variation among an International Group of Genetic Counselors on when to Offer Predictive Genetic Testing to Children at Risk of an Inherited Arrhythmia or Cardiomyopathy. J Genet Couns .2018 Aug 21. doi: 10.1007/s10897-018-0293-x.
Christians I.., van Engelen K.., van Langen I.M., Birnie E., Bonsel G.J., Elliott P.M., Wilde A.A.. Risk stratification for sudden cardiac death in hypertrophic cardiomyopathy: systematic review of clinical risk markers. Europace 2010; 12( 3): 313-321.47.
Czosek RJ. Arrhythmic Burden and Ambulatory Monitoring of Pediatric Patients with Cardiomyopathy / Czosek RJ, Jefferies JL, Khoury PR // Pacing Clin Electrophysiol. 2016;39(5):43–51.
Daubert C. Pacing for hypertrophic obstructive cardiomyopathy: an update and future directions. / Daubert C, Gadler F, Mabo P, Linde C. // Europace. 2018;20(6):908– 920.
Dearani JA. Surgery insight: Septal myectomy for obstructive hypertrophic cardiomyopathy — the Mayo Clinic experience / Dearani JA, Ommen SR, Gersh BJ et al. // Nat Clin Pract Cardiovasc Med. 2007; 4:503–512.
Decker JA, Rossano JW, Smith EO, Cannon B., Clunie S.K., Gates C., Jefferies J.L., Kim J.J., Price J.F., Dreyer W.J., Towbin J.A., Denfield S.W.. Risk factors and mode of death in isolated hypertrophic cardiomyopathy in children. J Am Coll Cardiol 2009; 54: 250-4.
Deng L. Numerical simulation study on systolic anterior motion of the mitral valve in hypertrophic obstructive cardiomyopathy / Deng L, Huang X, Yang C et al. // Int J Cardiol. 2018; 266:167–173.
Desai M. Risk stratification in hypertrophic cardiomyopathy / Desai M, Mentias A. // Aging (Albany NY). 2019; 11(6):1617–1618.
Di Cori A. Role of cardiac electronic implantable device in the stratification and management of embolic risk of silent atrial fibrillation: are all atrial fibrillations created equal? / Di Cori A, Lilli A, Zucchelli G, Zaca V. // Expert Rev Cardiovasc Ther. 2018;16(3):175–181.
Di Salvo G..., Pacileo G..., Limongelli G... Baldini L., Rea A., Verrengia M., D'Andrea A., Russo M.G., Calabrò R... Non sustained ventricular tachycardia in hypertrophic cardiomyopathy and new ultrasonic derived parameters. J Am Soc Echocardiogr 2010;23 :( 6): 581-590.
Dimitrow P.P., Chojnowska L., Rudzinski T.S. Piotrowski W., Ziólkowska L., Wojtarowicz A., Wycisk A., Dabrowska-Kugacka A., Nowalany-Kozielska E., Sobkowicz B., Wróbel W., Aleszewicz-Baranowska J, Rynkiewicz A., Loboz-Grudzien K., Marchel M., Wysokinski A.. Sudden death in hypertrophic cardiomyopathy: old risk factors reassessed in a new model of maximalized follow-up. Eur Heart J 2010; 31(24): 3084–3093,32
Debonnaire P, Katsanos S, Joyce E, et al. QRS fragmentation and QTc duration relate to malignant ventricular tachyarrhythmias and sudden cardiac death in patients with hypertrophic cardiomyopathy. J Cardiovasc Electrophysiol 2015; 26:547–555.
Dragulescu A, Mertens L, Friedberg MK.Interpretation of left ventricular diastolic dysfunction in children with cardiomyopathy by echocardiography: problems and limitations. . 2013 Mar 1; 6(2):254-61. doi: 10.1161/CIRCIMAGING.112.000175
Dubrey SW. Amyloid diseases of the heart: assessment, diagnosis, and referral / Dubrey SW, Hawkins PN, Falk RH. // Heart. 2011;97(1):75–84.
Dzemeshkevich SL. Reconstructive surgery for the diffuse-generalized form of hypertrophic cardiomyopathy / Dzemeshkevich SL, Frolova YuV, Sinitsin V et al. // WSCTS J. 2017;1(2):31–35.
Efthimiadis GK. An overview of pharmacotherapy in hypertrophic cardiomyopathy: current speculations and clinical perspectives. / Efthimiadis GK, Pagourelias E, Zegkos T et al. // Rev Cardiovasc Med. 2016;17(3–4):115—123.
Elliott P. Prevention of hypertrophic cardiomyopathy-related deaths: theory and practice / Elliott P, Spirito P. // Heart. 2008;94(10):69–75.
Elliott P.M., Anastasakis A., Borger M.A. . Borggrefe M.Cecchi F., Charron P. , Hagege A., Lafont A.,Limongelli G., Mahrholdt H.,.McKenna W.,Mogensen J., Nihoyannopoulos P., Nistri S., Rapezzi C.,. Rutten F,,Tillmanns C,Watkins H. 2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy The Task Force for the Diagnosis and Management of Hypertrophic cardiomyopathy of the European Society of Cardiology (ESC) //. 2014;35(39):2733– 2779. Eur Heart J 2014 /eurheartj/ehu284. www escardio.org
Elliott P.M., Gimeno J.R., Tome M.T. et al. Left ventricular outflow tract obstruction and sudden death risk in patients with hypertrophic cardiomyopathy. Eur Heart J 2006; 27(16): 1933–1941
Epstein SE. Verapamil: its potential for causing serious complication in patients with hypertrophic cardiomyopathy / Epstein SE, Rosing DR. // Circulation. 1981;64(3):37–41.
Expert Consensus Statement on the State of Genetic Testing for the Channelopathies and Cardiomyopathies HRS, EHRA 2011
Expert Consensus Statement on the Diagnosis and Management of Patients with Inherited Primary Arrhythmia Syndromes HRS, EHRA, APHRS 2013
Falk RH. Diagnosis and management of the cardiac amyloidoses / Falk RH. // Circulation. 2005; 112:2047–2060.
Farhad H. Left atrial structure and function in hypertrophic cardiomyopathy sarcomere mutation carriers with and without left ventricular hypertrophy / Farhad H, Seidelmann SB, Vigneault D et al. // J Cardiovasc Magn Reson. 2017; 19:1–10.
Fernández A. Fernández A., Vigliano C.A., Casabé J.H. Diez M., Favaloro L.E., Guevara E., Favaloro R.R., Laguens R.P . Comparison of Prevalence, Clinical Course, and Pathological Findings of Left Ventricular Systolic Impairment Versus Normal Systolic Function in Patients With Hypertrophic Cardiomyopathy. Am J Cardiol 2011; 108(4): 548–555
Ferreira PF, Kilner PJ, McGill LA, et al. In vivo cardiovascular magnetic resonance diffusion tensor imaging shows evidence of abnormal myocardial laminar orientations and mobility in hypertrophic cardiomyopathy. J Cardiovasc Magn Reson 2014; 16:87.
Finocchiaro G. Impact of Demographic Features, Lifestyle, and Comorbidities on the Clinical Expression of Hypertrophic Cardiomyopathy / Finocchiaro G, Magavern E, Sinagra G et al. //Journ Am Heart Assoc. 2017;6(12).
Finocchiaro G, Pinamonti B, Merlo M, Brun F, Barbati G, Sinagra G. Prognostic role of clinical presentation in symptomatic patients with hypertrophic cardiomyopathy. J Cardiovasc Med (Hagerstown) 2012; 13: 810-8.
Flachskampf FA. Recommendations for transoesophageal echocardiography: update 2010/ Flachskampf FA, Badano L, Daniel WG et al. // Eur. J. Echocardiogr. 2010;11:557–576.
Focused Update on New Pharmacological Therapy for Heart Failure: An Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure ACC, AHA, HFSA 2016
Fourey D, Care M, Siminovitch KA, Weissler-Snir A, Hindieh W, Chan RH, Gollob MH, Rakowski H, Adler A. Prevalence and Clinical Implication of Double Mutations in Hypertrophic Cardiomyopathy: Revisiting the Gene-Dose Effect. Circ Cardiovasc Genet. 2017 Apr; 10(2):e001685.
Frangini PA. How revealing are insertable loop recorders in pediatrics? / Frangini PA, Cecchin F, Jordao L et al. // Pacing Clin Electrophysiol. 2008; 3:38–43.
Frustaci A. Evolution of cardiac pathology in classic Fabry disease: progressive cardiomyocyte enlargement leads to increased cell death and fibrosis, and correlates with severity of ventricular hypertrophy / Frustaci A, Chimenti C, Doheny D, Desnick RJ. // Int J Cardiol. 2017;248:257–262.
Frustaci A. Diagnostic contribution of left ventricular endomyocardial biopsy in patients with clinical phenotype of hypertrophic cardiomyopathy / Frustaci A, Russo MA, Chimenti C. // Hum Pathol. 2013;44(1):33–41.
Galve E. Late benefits of dual-chamber pacing in obstructive hypertrophic cardiomyopathy: a 10-year follow-up study / Galve E, Sambola A, Saldana G et al. // Heart. 2010;96:2–6.
Garg L. Atrial fibrillation in hypertrophic cardiomyopathy: prevalence, clinical impact, and management / Garg L, Gupta M, Sabzwari SRA et al. // Heart Fail Rev. 2019:24(2);189–197.
Gersh BJ., Maron BJ, Bonow RO, Dearani JA, Fifer MA, Link MS, Naidu SS, Nishimura RA, Ommen SR, Rakowski H, Seidman CE, Towbin JA, Udelson JE, Yancy CW. 2011 ACCF/AHA guideline for the diagnosis and treatment of hypertrophic cardiomyopathy: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines // Circulation. 2011; 124(2):2761–2796.
Geske JB. Deformation patterns in genotyped patients with hypertrophic cardiomyopathy / Geske JB, Bos JM, Gersh BJ et al. // Eur Heart J Cardiovasc Imaging. 2014;15(4):56–65.
Gillmore JD. Non-biopsy diagnosis of cardiac transthyretin amyloidosis / Gillmore JD, Maurer MS, Falk RH et al .//Circulation. 2016;133:2404–2412.
Gistri R. Effect of verapamil on absolute myocardial blood nodalol and verapamil in mild and moderately symptomatic hypertrophic cardiomyopathy / Gistri R, Cecchi F, Choudhury L et al. // J Am Coll Cardiol. 1993;21:1672–1679.
Goff ZD. Sudden death related cardiomyopathies — hypertrophic cardiomyopathy. / Goff Z.D., Calkins H. // Prog Cardiovasc Dis. 2019;62(3):212–216.
Goyal V. Pathophysiology and prevention of sudden cardiac death / Goyal V, Jassal DS, Dhalla NS. // Can J Physiol Pharmacol. 2016;94(3):237–244.
Green JJ. Prognostic value of late gadolinium enhancement in clinical outcomes for hypertrophic cardiomyopathy / Green JJ, Berger JS, Kramer CM, Salerno M. // JACC Cardiovasc Imaging. 2012; 5:370–377.
Gudkova A. Diagnostic challenge in desmin cardiomyopathy with transformation of clinical phenotypes / Gudkova A, Kostareva A, Sjoberg G et al. // Pediatr Cardiol. 2013;34(2):67–70.
Guideline for the Management of Heart Failure8 ACC, AHA 2013
Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart Failure ESC 2016
Guideline for Management of Patients with Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death3 AHA, ACC, HRS 2017
Gutierrez-Barrios A. Invasive assessment of coronary microvascular dysfunction in hypertrophic cardiomyopathy: the index of microvascular resistance / GutierrezBarrios A, Camacho-Jurado F, Diaz-Retamino E et al. // Cardiovasc Revasc Med. 2015;16(7)426–428.
HSchaff HV. Expanding the indications for septal myectomy in patients with hypertrophic cardiomyopathy: results of operation in patients with latent obstruction / Schaff HV, Dearani JA, Ommen SR et al. // J Thorac Cardiovasc Surg. 2012; 143:303– 309.
Halpern DG. Echocardiography before and after resect-plicate-release surgical myectomy for obstructive hypertrophic cardiomyopathy / Halpern DG, Swistel DG, Po JR et al. // J Am Soc Echocardiogr. 2015;28(11):18–28.
Hang D. Combined transaortic and transapical approach to septal myectomy in patients with complex hypertrophic cardiomyopathy / Hang D, Schaff HV, Ommen SR, et al. // The Journal of Thoracic and Cardiovascular Surgery. 2018;155(5):2096–2102.
Harmon KG. The effectiveness of screening history, physical exam, and ECG to detect potentially lethal cardiac disorders in athletes: a systematic review / meta-analysis. / Harmon KG, Zigman M, Drezner JA. // J Electrocardiol. 2015:48(3);29–38.
Heffernan K.S., Maron M.S., Patvardhan E.A. et al. Relation of pulse pressure to blood pressure response to exercise in patients with hypertrophic cardiomyopathy. Am J Cardiol 2011; 107( 4): 600-603
Hernandez L.E. Myocardial stress perfusion magnetic resonance in children with hypertrophic cardiomyopathy. Cardiol Young. 2018 May;28(5):702-708. doi: 10.1017/S1047951118000094.
Hershberger RE. Genetic Evaluation of Cardiomyopathy A Heart Failure Society of America Practice Guideline./ Hershberger RE, Givertz MM, Ho CY et al. // J Card Fail. 2018; 24(5):278–302.
Hiemstra YL. Development of and progression of overt heart failure in nonobstructive hypertrophic cardiomyopathy / Hiemstra YL, Debonnaire P, van Zwet EW et al. // Am J Cardiol. 2018;122(4):656–662.
Ho CY. The Burden of Early Phenotypes and the Influence of Wall Thickness in Hypertrophic Cardiomyopathy Mutation Carriers: Findings From the HCMNet Study / Ho CY, Day SM, Colan SD et al. // HCMNet Investigators. JAMA Cardiol. 2017; 4:419– 428.
Hodatsu A. Compound heterozygosity deteriorates phenotypes of hypertrophic cardiomyopathy with founder MYBPC3 mutation: evidence from patients and zebrafish models. American journal of physiology / Hodatsu A, Konno T, Hayashi K, et al. // Heart and circulatory physiology. 2014; 307:1594–1604.
HRS expert consensus statement on evaluation, risk stratification, and management of arrhythmogenic cardiomyopathy. Heart Rhythm, Vol 16, No 11, 301-371. 2019
Huang J. Left ventricular short-axis systolic function changes in patients with hypertrophic cardiomyopathy detected by two-dimensional speckle tracking imaging / Huang J, Yan ZN, Rui YF et al. // BMC Cardiovasc Disord. 2018; 18(1).
Huang X. Assessment of left ventricular systolic and diastolic abnormalities in patients with hypertrophic cardiomyopathy using real-time three-dimensional echocardiography and two-dimensional speckle tracking imaging / Huang X, Yue Y, Wang Y et al. // Cardiovasc Ultrasound. 2018;16(1):23.
Hymel BJ. Echocardiographic assessment of systolic anterior motion of the mitral valve / Hymel BJ, Townsley MM. // Anesth Analg. 2014; 118:1197–1201.
Ibrahim M. Modern management of systolic anterior motion of the mitral valve / Ibrahim M, Rao C, Ashrafian H, et al. // Eur J Cardiothorac Surg. 2012;41:.60–70.
Inada K. Substrate characterization and catheter ablation for monomorphic ventricular tachycardia in patients with apical hypertrophic cardiomyopathy / Inada K, Seiler J, Roberts-Thomson KC et al. // J Cardiovasc Electrophysiol. 2011; 22:41–48.
Ingles J, Burns C, Bagnall RD, et al.. Nonfamilial hypertrophic cardiomyopathy: prevalence, natural history, and clinical implications.Circ Cardiovasc Genet. 2017; 10:e001620.
Ismail TF. Coronary microvascular ischemia in hypertrophic cardiomyopathy — a pixel-wise quantitative cardiovascular magnetic resonance perfusion study / Ismail TF, Hsu LY, Greve AM et al. // J Cardiovasc Magn Reson. 2014;16:49.
Iwai S. Sudden Cardiac Death Risk Stratification and the Role of the Implantable Cardiac Defibrillator. Cardiol Clin. 2019 Feb;37(1):63-72. doi: 10.1016/j.ccl.2018.08.011.
Janoušek J, Kubuš P.What's new in cardiac pacing in children? Curr Opin Cardiol . 2014 Jan;29(1):76-82. doi: 10.1097/HCO.0000000000000025
Kaple RK. Mitral valve abnormalities in hypertrophic cardiomyopathy: echocardiographic features and surgical outcomes / Kaple RK, Murphy RT, Di Paola LM et al. // Ann Thorac Surg. 2008;85:1527–1535.
Kaski JP, Syrris P, Esteban MT, Jenkins S, Pantazis A, Deanfield JE, McKenna WJ, Elliott PM. Prevalence of sarcomere protein gene mutations in preadolescent children with hypertrophic cardiomyopathy. Circ Cardiovasc Genet. 2009 Oct;2(5):436-41.
Kelly MA. Adaptation and validation of the ACMG/AMP variant classification framework for MYH7-associated inherited cardiomyopathies: recommendations by ClinGen’s inherited cardiomyopathy expert panel / Kelly MA, Caleshu C, Morales A et al. // Genet Med. 2018;20(3):351–359.
M. Kelly, C. Semsarian. Multiple mutations in genetic cardiovascular disease: a marker of disease severity? Circ Cardiovasc Genet, 2 (2009), pp. 182-190
Killu AM. Cardiac resynchronization therapy in patients with end-stage hypertrophic cardiomyopathy. / Killu AM, Park JY, Sara JD et al. // Europace. 2018;20(1):82–88.
Kindel SJ, Miller EM, Gupta R, Cripe LH, Hinton RB, Spicer RL, Towbin JA, Ware SM. Pediatric cardiomyopathy: importance of genetic and metabolic evaluation. J Card Fail. 2012 May;18(5):396-403.
Kirchhof P. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS / Kirchhof P, Benussi S, Kotecha D et al. // European Heart Journal. 2016;37:2893–2962.
Kofflard M.J., Ten Cate F.J., van der Lee C., van Domburg R.T. Hypertrophic cardiomyopathy in a large community-based population: clinical outcome and identification of risk factors for sudden cardiac death and clinical deterioration. J Am Coll Cardiol 2003; 41(6): 987–993
Kokado H. Clinical features of hypertrophic cardiomyopathy caused by a Lys183 deletion mutation in the cardiac troponin I gene / Kokado H, Shimizu M, Yoshio H et al. // Circulation. 2000;102(6):663–669.
Konta L, Franklin R.C.G., Kaski J.P. Nomenclature and systems of classification for cardiomyopathy in children Cardiol Young . 2015 Aug;25 Suppl 2:31-42. doi: 10.1017/S1047951115001201.
Kostareva A. Deletion in TNNI3 gene is associated with restrictive cardiomyopathy / Kostareva A, Gudkova A, Sjoberg G et al. // International journal of cardiology. 2009;131 (3):410–412.
Kostareva A, Gudkova A, Sjoberg G et al. Desmin mutations in a St. Petersburg cohort of cardiomyopathies // Acta myologica: myopathies and cardiomyopathies: official journal of the Mediterranean Society of Myology / Edited by the Gaetano Conte Academy for the study of striated muscle diseases. 2006;25(3):109–115.
Kostera-Pruszczyk A. Diversity of cardiomyopathy phenotypes caused by mutations in desmin / Kostera-Pruszczyk A. // Journal of Cardiology. 2008;131:146–147.
Kubo T. Prevalence, clinical significance, and genetic basis of hypertrophic cardiomyopathy with restrictive phenotype./ Kubo T, Gimeno JR, Bahl A et al. // J Am Coll Cardiol. 2007;49:2419–2426.
Kubo T., Kitaoka H., Okawa M. Hirota T., Hayato K., Yamasaki N., Matsumura Y., Yabe T., Takata J., Doi Y.L. . Clinical impact of atrial fbrillation in patients with hypertrophic cardiomyopathy: Results from Kochi RYOMA Study. Circ J 2009; 73(9): 1599–160550
Kwon DH. Cardiac magnetic resonance detection of myocardial scarring in hypertrophic cardiomyopathy: correlation with histopathology and prevalence of ventricular tachycardia / Kwon DH, Smedira NG, Rodriguez ER et al. // J Am Coll Cardiol. 2009;54:242–249.
Lafreniere- Roula .M., Bolkier Y., Zahavich L., Mathew J., George K., Wilson J. et. al. Family screening for hypertrophic cardiomyopathy: Is it time to change practice guidelines? Eur Heart J. 2019 Dec 1;40(45):3672-3681. doi: 10.1093/eurheartj/ehz396.
Lambiase PD. Worldwide experience with a totally subcutaneous implantable defibrillator: early results from the EFFORTLESS S-ICD Registry / Lambiase PD, Barr C, Theuns DA et al. // Eur Heart J. 2014;35(25):1657–1665.
Lancellotti P. The clinical use of stress echocardiography in non-ischaemic heart disease: recommendations from the European Association of Cardiovascular Imaging and the American Society of Echocardiography. / Lancellotti P, Pellikka PA, Budts W. // Eur Heart J Cardiovasc Imaging. 2016;17(11):1191–1229.
Lang RM. Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. / Lang RM, Badano LP, MorAvi V et al. // Eur Heart J Cardiovasc Imaging. 2015;16(3):233–270.
LeeTM, HsuDT, KantorP, TowbinJA, WareSM, ColanSD, ChungWK, JefferiesJL, RossanoJW, CastleberryCD, AddonizioLJ, LalAK, LamourJM, MillerEM, ThrushPT, CzachorJD, RazokyH, HillA, LipshultzSE. Pediatric Cardiomyopathies. Circ Res. 2017 Sep 15; 121(7):855-873. doi: 10.1161/CIRCRESAHA.116.309386.
Leonardi RA. Meta-analyses of septal reduction therapies for obstructive hypertrophic cardiomyopathy: comparative rates of overall mortality and sudden cardiac death after treatment / Leonardi RA, Kransdorf EP et al. // Circ Cardiovasc Interv. 2010;3:97–104.
Leone O. 2011 consensus statement on endomyocardial biopsy from the Association for European Cardiovascular Pathology and the Society for Cardiovascular Pathology / Leone O, Veinot JP, Angelini A et al. // Cardiovasc. Pathol. 2012;21:245– 274.
Leslie N., Bailey L. Pompe Disease. In: GeneReviews® [Internet]. Seattle. Updated 2017. PMID: 20301438 Bookshelf ID: NBK1261
Lipshultz SE, Orav EJ, Wilkinson JD, et al. Risk stratification at diagnosis for children with hypertrophic cardiomyopathy: an analysis of data from the Pediatric Cardiomyopathy Registry. Lancet (London, England). 2013; 382(9908):1889–1897.
Liu W. Diastolic dysfunction of hypertrophic cardiomyopathy genotype-positive subjects without hypertrophy is detected by tissue doppler imaging: a systematic review and meta-analysis / Liu W, Sun D, Yang J. // Journal of Ultrasound in Medicine. 2017; 36(10):2093–2103.
Lopes LR. Use of high-throughput targeted exome-sequencing to screen for copy number variation in hypertrophic cardiomyopathy / Lopes LR, Murphy C, Syrris P et al. // Eur J Med Genet. 2015; 58(11):611–616.
Lund LH. International Society for Heart and Lung Transplantation The Registry of the International Society for Heart and Lung Transplantation: Thirty-fourth Adult Heart Transplantation Report-2017; Focus Theme: Allograft ischemic time. / Lund LH, Khush KK, Cherikh WS et al. //J Heart Lung Transplant. 2017;36(10):1037–1046.
Malcić I, Jelasić D, Sarić D, Kniewald H, Jelusić M, Rojnić-Putarek N, Sćukanec M, Pazanin L, Dilber D.Diagnostic value of myocardial biopsy in the diagnostic algorithm in cardiomyopathies in children. Lijec Vjesn . Sep-Oct 2004;126(9-10):227-34.
Malhotra A. Hypertrophic Cardiomyopathy in Athletes / Malhotra A, Sharma S. // Eur Cardiol. 2017;12(2):80–82.
Manabe S. Management of systolic anterior motion of the mitral valve: a mechanism-based approach / Manabe S, Kasegawa H, Arai H, Takanashi S. // Gen Thorac Cardiovasc Surg. 2018;66(7):379–389.
Marian AJ. Hypertrophic cardiomyopathy: genetics, pathogenesis, clinical manifestations, diagnosis, and therapy / Marian AJ, Braunwald E. // Circ Res. 2017; 12 1(7):749–770.
Maron BJ. Prevalence of hypertrophic cardiomyopathy in a general population of young adults. Echocardiographic analysis of 4111 subjects in the CARDIA Study. Coronary Artery Risk Development in (Young) Adults / Maron BJ, Gardin JM, Flack JM et al. // Circulation. 1995;92(4:785–789.
Maron BJ. Epidemiology of hypertrophic cardiomyopathy-related death: revisited in a large non-referral-based patient population / Maron BJ, Olivotto I, Spirito P et al. // Circulation. 2000;102(8:858–864.
Maron BJ. Clinical course of hypertrophic cardiomyopathy with survival to advanced age / Maron BJ, Casey SA, Hauser RG, Aeppli DM. // J Am Coll Cardiol. 2003;42 (5):882–888.
Maron BJ. Moving beyond the sarcomere to explain heterogenity in hypertrophic cardiomyopathy: JACC review topic of the week / Maron BJ, Maron MS, Maron BA, Loscalzo JJ. // Am Coll Cardiol. 2019;73(15):1978–1986.
Maron BJ. Assessment of permanent dual-chamber pacing as a treatment for drugrefractory symptomatic patients with obstructive hypertrophic cardiomyopathy. A randomized, double-blind, crossover study (M-PATHY) / Maron BJ, Nishimura RA, McKenna WJ et al. // Circulation. 1999;99:2927–2933.
Maron BJ. Clinical profile of stroke in 900 patients with hypertrophic cardiomyopathy / Maron BJ, Olivotto I, Bellone P et al. //J Am Coll Cardiol. 2002; 39:301–307.
Maron BJ. Cardiac disease in young trained athletes. Insights into methods for distinguishing athlete's heart from structural heart disease, with particular emphasis on hypertrophic cardiomyopathy / Maron BJ, Pelliccia A, Spirito P. // Circulation. 1995;91(5):1596–1601.
Maron BJ. Non-obstructive hypertrophic cardiomyopathy out of the shadows: known from the beginning but largely ignored until now / Maron BJ, Rowin EJ, Maron MS, Braunwald E. // Am J Med. 2017; 130(2):119–123.
Maron BJ. Clinical spectrum and management of heart failure in hypertrophic cardiomyopathy. / Maron BJ, Rowin EJ, Udelson JE, Maron MS. // JACC Heart Fail.2018;5:353–363.
Maron B.J. Risk Stratification and Role of Implantable Defbrillators for Prevention of Sudden Death in Patients With Hypertrophic Cardiomyopathy. Circ J 2010; 74 (11): 2271-228225
Maron B.J., Doerer J.J., Haas T.S., Tierney D.M., Mueller F.O. Sudden deaths in young competitive athletes: analysis of 1866 deaths in the United States, 1980–2006. Circulation. 2009; 119(8):1085–1092.8,25
Maron BJ, Tajik AJ, Ruttenberg HD, et al. Hypertrophic cardiomyopathy in infants: clinical features and natural history. Circulation 1982; 65: 7-17.
Maron B.J., M.S. Maron, C. Semsarian. Double or compound sarcomere mutations in hypertrophic cardiomyopathy: a potential link to sudden death in the absence of conventional risk factors. Heart Rhythm, 9 (2012), pp. 57-63
Maron MS. Prevalence, clinical significance, and natural history of left ventricular apical aneurysms in hypertrophic cardiomyopathy / Maron MS, Finley JJ, Bos JM et al. // Circulation. 2008;118:1541–1549.
Maron MS. Effect of spironolactone on myocardial fibrosis and other clinical variables in patients with hypertrophic cardiomyopathy / Maron MS, Chan RH, Kapur NK et al. // Am J Med. 2018;131(7):837–841.
Maron MS. Right ventricular involvement in hypertrophic cardiomyopathy / Maron MS, Hauser TH, Dubrow E et al. // Am J Cardiol. 2007; 100:1293–1298. 237.Maron MS. The case for myocardial ischemia in hypertrophic cardiomyopathy / Maron MS, Olivotto I, Maron BJ et al. // J Am Coll Cardiol. 2009;54(9):66–75.
Maron MS. Contemporary natural history and management of nonobstructive hypertrophic cardiomyopathy / Maron MS, Rowin EJ, Olivotto I et al. // J Am Coll Cardiol. 2016; 67(12):1399–1409.
Maron MS, Olivotto I, Betocchi S, et al. Effect of left ventricular outflow tract obstruction on clinical outcome in hypertrophic cardiomyopathy. N Engl J Med 2003; 348: 295-303.
Maron B., Rowin E., Casey S., Lesser J, Garberich, R, MS. Hypertrophic Cardiomyopathy in Children, Adolescents, and Young Adults Associated With Low Cardiovascular Mortality With Contemporary Management Strategies Circulation. 2016;133(1):62-73.24.
Maron B., Spirito P., Ackerman M. Casey S., Semsarian, C., Estes N. Shannon K., Ashley E., Day S., Pacileo G., Formisano F., , Aristidis E. BosE., Woo A. Autore C.Pass R., Boriani G., Garberich R., Almquist A., Russel M., Boni L., Berger S., Maron M. Link M. Prevention of Sudden Cardiac Death With Implantable Cardioverter-Defibrillators in Children and Adolescents With Hypertrophic Cardiomyopathy. J Amer Coll Cardiol 2013; 61( 14): 1527-1535
Marrakchi S. Risk stratification in hypertrophic cardiomyopathy / Marrakchi S, Kammoun I, Bennour E et al. // Herz. 2018; doi: 10.1007/s00059-018-4700-8.
Marwick TH. Benefits of intraoperative echocardiography in the surgical management of hypertrophic cardiomyopathy / Marwick TH, Stewart WJ, Lever HM et al. // J Am Coll Cardiol. 1992; 20:1066–1072.
Maskatia SA. Restrictive physiology is associated with poor outcomes in children with hypertrophic cardiomyopathy / Maskatia SA, Decker JA et al. // Pediatr Cardiol. 2011;4.
Maskatia SA, Decker JA, Spinner JA, et al. Restrictive physiology is associated with poor outcomes in children with hypertrophic cardiomyopathy. Pediatr Cardiol 2012; 33: 141-9.
Mathew J, Zahavich L, Lafreniere-Roula M, et al... Utility of genetics for risk stratification in pediatric hypertrophic cardiomyopathy.Clin Genet. 2018; 93:310–9.
Matsubara H, Nakatani S, Nagata S, et al. Salutary effect of disopyramide on left ventricular diastolic function in hypertrophic obstructive cardiomyopathy. J Am Coll Cardiol 1995; 26: 768-75.
Maurizi N, Passantino S, Spaziani G, et al. Long-term outcomes of pediatric-onset hypertrophic cardiomyopathy and age-specific risk factors for lethal arrhythmia events. JAMA Cardiol 2018; 3:520–525.
Mazzarotto F., Olivotto I., Boschi B., Girolami F., Poggesi C Barton P.J.R., Walsh R. et al. Contemporary Insights Into the Genetics of Hypertrophic Cardiomyopathy: Toward a New Era in Clinical Testing? J Am Heart Assoc. 2020 Apr 21;9(8):e015473. doi: 10.1161/JAHA.119.015473. Epub 2020 Apr 18.
McKenna WJ, Goodwin JF. The natural history of hypertrophic cardiomyopathy. Current problems in cardiology. 1981;6(4):1–26.
McMurray JJ. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC / McMurray JJ, Adamopoulos S, Anker SD et al. // Eur Heart J. 2012;33:1787–1847.
Mehra MR. Listing criteria for heart transplantation: International Society for Heart and Lung Transplantation guidelines for the care of cardiac transplant candidates - 2006 / Mehra MR, Kobashigawa J, Starling R et al // J Heart Lung Transplant. 2006;25:1024–1042
Mentias A. Late Gadolinium Enhancement in Patients With Hypertrophic Cardiomyopathy and Preserved Systolic Function / Mentias A, Raeisi-Giglou P, Smedira NGet al. // J Am Coll Cardiol. 2018; 72:857–70.
Mestres CA, Bartel T, Sorgeute A et al. Hypertrophic obstructive cardiomyopathy: what, when, why, for whom / Mestres CA, Bartel T, Sorgeute A et al. // Eur J Cardiovasc Surg. 2018;53:700–707.
MDesai M. Risk stratification in hypertrophic cardiomyopathy / Desai M, Mentias A. // Aging (Albany NY). 2019;11(6):1617–1618.
Miller CAS. Safety, Side Effects and Relative Efficacy of Medications for Rhythm Control of Atrial Fibrillation in Hypertrophic Cardiomyopathy / Miller CAS, Maron MS, Estes NAM III et al. //Am J Cardiol. 2019;123(11):1859–1862.
Minami Y. Clinical implications of midventricular obstruction in patients with hypertrophic cardiomyopathy / Minami Y, Kajimoto K, Terajima Y et al. //J Am Coll Cardiol. 2011; 57:46–55.
Miron A, Lafreniere-R.M., Steve Fan Chun-Po, Armstrong K.R., Dragulescu A., Papaz T. et al. A Validated Model for Sudden Cardiac Death Risk Prediction in Pediatric Hypertrophic Cardiomyopathy Circulation. 2020 Jul 21;142(3):217-229. doi: 10.1161/CIRCULATIONAHA.120.047235.
Mitchell C. Guidelines for performing a comprehensive transthoracic echocardiographic examination in adults: recommendations from the american society of echocardiography. / Mitchell C, Rahko PS, Blauwet LA et al. // J Am Soc Echocardiogr. 2019;32(1):1–64.
Mittal SR. Isolated right ventricular hypertrophic obstructive cardiomyopathy / Mittal SR. // J Assoc Phys India. 2010;58:49–50.
Moak JP, Leifer ES, Tripodi D, et al. Long-term follow up of children and adolescents diagnosed with hypertrophic cardiomyopathy: Risk factors for adverse arrhythmic events. Pediatr Cardiol 2011; 32(8): 1096–1105
Monserrat L. Prevalence of Fabry disease in a hogort of 508 unrelated patients with hypertrophic cardiomyopathy. / Monserrat L, Gimeno-Blanes JR, Marin F et al. // J Am Coll Cardiol. 2007;50:2399–2403.
Monserrat L., Elliott P., Gimeno J. Non-Sustained Ventricular Tachycardia in Hypertrophic Cardiomyopathy: An Independent Marker of Sudden Death Risk in Young Patients J Amer Coll Cardiol 2003; 42:( 5): 873-878.
Morita H, Rehm HL, Menesses A, McDonough B, Roberts AE, Kucherlapati R, Towbin JA, Seidman JG, Seidman CE. Shared genetic causes of cardiac hypertrophy in children and adults. N Engl J Med. 2008 May 1;358(18):1899-908.
Nagueh SF. Recommendations for the evaluation of left ventricular diastolic function by echocardiography / Nagueh SF, Appleton CP, Gillebert TC et al. // Eur J Echocardiogr. 2009; 10:165–193.
Nakamura T. Increased plasma brain naturetic peptide level as a guide for silent myocardial ischemia in patients with non-obstructive hypertrophic cardiomyopathy. / Nakamura T, Sakamoto K, Tetsuhiro Y et al. // J Am Coll Cardiol. 2002;39: 57–63.
Nakanoa S.J., Menonb S.C. Risk stratification in pediatric hypertrophic cardiomyopathy: Insights for bridging the evidence gap? Prog Pediatr Cardiol. 2018 June ; 49: 31–37. doi:10.1016/j.ppedcard.2018.03.001.
Nishimura RA. Septal myectomy for patients with hypertrophic cardiomyopathy: a new paradigm / Nishimura RA., Schaff HV. // J Thorac Cardiovasc Surg. 2016; 151:303–304.
Nistri S. Timing and significance of exercise-induced left ventricular outflow tract pressure gradients in hypertrophic cardiomyopathy / Nistri S, Olivotto I, Maron MS et al. // Am J Cardiol. 2010;106:1301–1306.
Norrish G, Cantarutti N, Pissaridou E, Ridout D, Limongell G,Elliott P., Kaski J.. Risk factors for sudden cardiac death in childhood hypertrophic cardiomyopathy: A systematic review and meta-analysis. Eur J Prev Cardiol. 2017 2047487317702519.
Norrish G., T. Ding, E. Field, L. Ziółkowska, I. Olivotto, G. Limongelli, A. Anastasakis, R. Weintraub, et al. Development of a Novel Risk Prediction Model for Sudden Cardiac Death in Childhood Hypertrophic Cardiomyopathy (HCM Risk-Kids). JAMA Cardiol. 2019; 4(9):918-927. doi:10.1001/jamacardio.2019.2861.
Norrish G. , Ding T., Field E., McLeod E., Ilina M., Stuart G. et al. A validation study of the European Society of Cardiology guidelines for risk stratification of sudden cardiac death in childhood hypertrophic cardiomyopathy. Europace. 2019 Oct 1;21(10):1559-1565. doi: 10.1093/europace/euz118.
Norrish G, Field E, Mcleod K, et al. Clinical presentation and survival of childhood hypertrophic cardiomyopathy: a retrospective study in United Kingdom. Eur Heart J. 2019;40(12):986-993. doi:10.1093/eurheartj/ehy798.
Norrish G, Kaski JP. Risk stratification in childhood hypertrophic cardiomyopathy, Global Cardiology Science and Practice 2018:24 https://doi.org/10.21542/gcsp.2018.24
Norrish G., Jager J., Field E, Quinn E., Fell H., Lord E. Yield of Clinical Screening for Hypertrophic Cardiomyopathy in Child First-Degree Relatives. Circulation. 2019 Jul 16;140(3):184-192. doi: 10.1161/CIRCULATIONAHA.118.038846.
Nugent AW, Daubeney PE, Chondros P, et al. The epidemiology of childhood cardiomyopathy in Australia. N Engl J Med. 2003;348(17):1639–1646.
Nugent AW, Daubeney PE, Chondros P, et al. Clinical features and outcomes of childhood hypertrophic cardiomyopathy: results from a national population-based study. Circulation. 2005;112(9):1332–1338.
O'Connor MJ. Disopyramide use in infants and children with hypertrophic cardiomyopathy / O'Connor MJ, Miller K, Shaddy RE et al. // Cardiol Young. 2018;4):530–535.
O’Hanlon R. Prognostic significance of myocardial fibrosis in hypertrophic cardiomyopathy / O’Hanlon R, Grasso A, Roughton M et al. // J Am Coll Cardiol. 2010;56:867–874.
O’Mahony C, Jichi F, Pavlou M, Monserrat L, Anastasakis A, Rapezzi C, Biagini E, Gimeno JR, Limongelli G, McKenna WJ, Omar RZ, Elliott PM. A novel clinical risk prediction model for sudden cardiac death in hypertrophic cardiomyopathy(HCM Risk-SCD). Eur Heart J 2014 35(30):2010-20.30
Okayama S. Role of cardiac computed tomography in planning and evaluating percutaneous transluminal septal myocardial ablation for hypertrophic obstructive cardiomyopathy / Okayama S, Uemura S, Soeda T et al .// J Cardiovasc Comput Tomogr. 2010;4:62–65.
Olivotto I. Clinical utility and safety of exercise testing inpatients with hypertrophic cardiomyopathy / Olivotto I, Montereggi A, Mazzuoli F, Cecchi F. // G. Ital. Cardiol. 1999; 29:11–19.
Olivotto I. Microvascular function is selectively impaired in patients with hypertrophic cardiomyopathy and sarcomere myofilament gene mutations / Olivotto I, Girolami F, Sciagra R et al. // J Am Coll Cardiol. 2011–; .58(8):839–848.
Orme NM. Comparison of surgical septal myectomy to medical therapy alone in patients with hypertrophic cardiomyopathy and syncope / Orme NM, Sorajja P, Dearani JA et al. // Am J Cardiol. 2013;111:388–392.
Östman-Smith I. Hypertrophic cardiomyopathy in childhood and adolescence - strategies to prevent sudden death. Fundam Clin Pharmacol 2010; 24: 637-52.
Östman-Smith I, Keeton B, Wettrell G. Effect of medical therapy in childhood hypertrophic cardiomyopathy with risk factors for heart failure-related deaths. Cardiol Young 2008; 18: S10.
Östman-Smith I, Wettrell G, Keeton B, Holmgren D, Ergander U, Gould S, Bowker C, Verdicchio M. Age- and genderspecific mortality rates in childhood hypertrophic cardiomyopathy. Eur Heart J 2008; 29: 1160-7.
Ostman-Smith I., Sjöberg G., Rydberg A., Larsson P., Fernlund E. A Predictors of Risk for Sudden Death in Childhood Hypertrophic Cardiomyopathy: The Importance of the ECG Risk Score Open Heart. 2017 Oct 21; 4(2):e000658.
Ouellette AC, Mathew J, Manickaraj AK, Manase G, Zahavich L, Wilson J, George K, Benson L, Bowdin S, Mital S.Clinical genetic testing in pediatric cardiomyopathy: Is bigger better? Clin Genet .2018 Jan; 93(1):33-40. doi: 10.1111/cge.13024.
Pacileo G. Hypertrophic cardiomyopathy in pediatric patients: effect of verapamil on regional and global left ventricular diastolic function / Pacileo G, De Cristofaro M, Russo MG et al. / Can J Cardiol. 2000; 16:146–152.
Pagourelias ED. Efficacy of various “classic” echocardiographic and laboratory indices in distinguishing the “gray zone” between athlete’s heart and hypertrophic cardiomyopathy: a pilot study. / Pagourelias ED, Efthimiadis GK, Kouidi E, Zorou P, Giannoglou G, Deligiannis A, Athyros VG, Karagiannis A, Geleris P. // Echocardiography. 2013; 30:131–139.
Pagourelias ED. Prognostic value of right ventricular diastolic function indices in hypertrophic cardiomyopathy. / Pagourelias ED, Efthimiadis GK, Parcharidou DG et al. // Eur J Echocardiogr. 2011;12(11):809–817.
Parato VM, Echocardiographic diagnosis of the different phenotypes of hypertrophic cardiomyopathy / Parato VM, Antoncecchi V, Sozzi F et al. (Italian Chapter of ISCU) //Cardiovasc Ultrasound. 2016;14(1):30.
Pasqualucci D. Clinical spectrum, therapeutic options, and outcome of advanced heart failure in hypertrophic cardiomyopathy / Pasqualucci D, Fornaro A, Castelli G et al. // Circ Heart Fail. 2015; 8:1014–1021.
Pelliccia A. Recommendations for participationin competitive sport and leisuretime physical activity in individuals with cardiomyopathies, myocarditis and pericarditis / Pelliccia A, Corrado D, Bjornstad HH et al. // Eur J Cardiovasc Prev Rehabil. 2006;13:876–885.
Philipson DJ. Emerging pharmacologic and structural therapies for hypertrophic cardiomyopathy / Philipson DJ, DePasquale EC, Yang EH, Baas AS. // Heart Failure Reviews. 2017;22(6):879–888.
Philipson DJ. Risk factors for atrial fibrillation in hypertrophic cardiomyopathy / Philipson DJ, Rader F, Siegel RJ. // Eur J Prev Cardiol. 2019;2047487319828474. doi: 10.1177/2047487319828474.
Pieles GE, Stuart AG. The adolescent athlete's heart; A miniature adult or grown-up child? Clin Cardiol . 2020 Aug;43(8):852-862. doi: 10.1002/clc.23417.
Plant-Bordeneuve V. Familial amyloid polyneuropathy. / Plant-Bordeneuve V, Said G. // Lancet Neurol. 2011;10:1086–1097.
Pinamonti B., Merlo M., Nangah R. et al. The progression of left ventricular systolic and diastolic dysfunctions in hypertrophic cardiomyopathy: clinical and prognostic significance. J Cardiovasc Med (Hagerstown) 2010; 11( 9): 669-677.
Prasad K, Williams L, Campbell R, Elliott PM, McKenna WJ, Frenneaux M. Episodic syncope in hypertrophic cardiomyopathy: evidence for inappropriate vasodilation.Heart 2008;94(10):1312–1317
Raissuni Z. Hypertrophic cardiomyopathy mimicking STEMI: The role of cardiac magnetic resonance imaging in the detection of microvascular coronary dysfunction / Raissuni Z, Doghmi N, Mousseaux E et al. // Diagn Interv Imaging. 2014;95(11):1111– 1112.
Rapezzi C. Diagnostic work-up in cardiomyopathies: bridging the gap between clinical phenotypes and final diagnosis. A position statement from the ESC Working Group on Myocardial and Pericardial Diseases / Rapezzi C, Arbustini E, Caforio AL, et al. // Eur Heart J. 2013;34:1448–1458.
Rapezzi C. Disease profile and differential diagnosis of hereditary transthyretinrelated amyloidosis with exclusively cardiac phenotype: an Italian perspective / Rapezzi C, Quarta CC, Obici L. et al. // Eur Heart J. 2013;34:520–528.
Raphael CE. Mechanisms of myocardial ischemia in hypertrophic cardiomyopathy, insights from wave intensity analysis and magnetic resonance / Raphael CE, Cooper R, Parker KH et al. // J Am Coll Cardiol. 2016;68:1651–1660.
Rare diseases task force. European Reference Networks in the Field of Rare Diseases: State of the Art and Future. 2008.
Richards S. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of thе American College of medical genetics and Genomics and the association for Molecular Pathology / Richards S, Aziz N, Bale S et al. // Genet Med. 2015;17(5):405–424.
Rogers DP. Effect of biventricular pacing on symptoms and cardiac remodelling in patients with end-stage hypertrophic cardiomyopathy. / Rogers DP, Marazia S, Chow AW et al. // Eur J Heart Fail. 2008;10:507–513.
Roman AJ. Sequential atrioventricular pacing in patients with hypertrophic cardiomyopathy: an 18-year experience. / Roman AJ, Cabezas J, Alonso BR et al. // Rev Esp Cardiol. 2016;69:377–383.
Rosing DR. Verapamil therapy: a new approach to the pharmacologic treatment of hypertrophic cardiomyopathy: III. Effects of long-term administration / Rosing DR, Condit JR, Maron BJ et al. // Am J Cardiol. 1981;48(3):545–553.
Rowin EJ, Sridharan A, Madias C, Firely C, Koethe B, Link MS, Maron MS, Maron BJ Prediction and Prevention of Sudden Death in Young Patients ( <20 years) With Hypertrophic Cardiomyopathy Am J Cardiol. 2020 Aug 1;128:75-83. doi: 10.1016/j.amjcard.2020.04.042
Sado DM. Identification and assessment of Anderson-Fabry disease by cardiovascular magnetic resonance noncontrast myocardial T1 mapping / Sado DM, White SK, Piechnik SK et al. // Circ. Cardiovasc. Imaging. 2013;6:392–398.
Sandoe JA. Guidelines for the diagnosis, prevention and management of implantable cardiac electronic device infection / Sandoe JA, Barlow G, Chambers JB, et al. // J Antimicrob Chemother. 2015;70:325–359.
Sarkozy A. Leopard syndrome / Sarkozy A, Digilio MC, Dallapiccola B. // Orphanet J Rare Dis. 2008;3(1):13.
Scaglia F. Clinical spectrum, morbidity, and mortality in 113 pediatric patients mitochondrial disease. / Scaglia F, Towbin JA, Craigen WJ et al. // Pediatrics. 2004;114:925–931.
Schönland SO. Immunohistochemistry in the classification of systemic forms of amyloidosis: a systematic investigation of 117 patients / Schönland SO, Hegenbart U, Bochtler T, Mangatter A, Hansberg M, Ho AD, Lohse P, Rocken C. // Blood. 2012;12:488–493.
Sciagr R. Myocardial blood flow and left ventricular functional reserve in hypertrophic cardiomyopathy: a 13NH3 gated PET study. / Sciagr R, Calabretta R, Cipollini F et al. // Eur J Nucl Med Mol Imaging. 2017;44(5):866–875.
Seferovi PM. Heart failure in cardiomyopathies: a position paper from the Heart Failure Association of the European Society of Cardiology / Seferovi PM, Polovina M, Bauersachs J // Eur J Heart Fail. 2019;21(5:553–576
Seggewi H. Syncope in hypertrophic (obstructive) cardiomyopathy / Seggewi H, Koljaja-Batzner A, Seggewi K, Meesmann M // Herzschrittmacherther Elektrophysiol. 2018;29(2):178–182.
Shah JP. Prevalence and Prognostic Significance of Right Ventricular Dysfunction in Patients With Hypertrophic Cardiomyopathy / Shah JP, Yang Y, Chen S, et al. // Am J Cardiol. 2018;122(11):1932–1938.
Shimada YJ. Effects of Losartan on Left Ventricular Hypertrophy and Fibrosis in Patients With Nonobstructive Hypertrophic Cardiomyopathy / Shimada YJ, Passeri JJ, Baggish AL et.al. // JACC Heart Fail. 2013;1(6):480–487.
Shlyakhto EV. Cellular aspects of pathogenesis of hypertrophic cardiomyopathy: role of cardiomyocyte polyploidy and activation of nuclear antigen of the proliferating cell in myocardium / Shlyakhto EV, Bokeria LA, Rybakova MG et al. // Cell and Tissue Biology. 2007; 1(6):689–693.
Solano A. Incidence, diagnostic yield and safety of the implantable loop-recorder to detect the mechanism of syncope in patients with and without structural heart disease / Solano A, Menozzi C, Maggi R, Donateo P, Bottoni N, Lolli G et al. // Eur Heart J. 2004;25:1116–1119.
Spicer RL. Hemodynamic effects of verapamil in children and adolescents with hypertrophic cardiomyopathy. / Spicer RL, Rocchini AP, Crowley DC et al. // Circulation. 1983;67:413–420.
Spirito P. Risk of sudden death and outcome in patients with hypertrophic cardiomyopathy with benign presentation and without risk factors / Spirito P, Autore C, Formisano F et al. // Am J Cardiol. 2014;113(9):1550–1155.
Stassano P. Mitral valve replacement and limited myectomy for hypertrophic obstructive cardiomyopathy: a 25-year follow-up / Stassano P, Di Tommaso L, Triggiani D et al. // Tex Heart Inst J. 2004; 31:137–142.
Steinmetz M, Krause U, Lauerer P, et al. Diagnosing ARVC in pediatric patients applying the revised task force criteria: importance of imaging, 12-Lead ECG, and genetics. Pediatr Cardiol 2018;39:1156–1164.
Schulz JB, Boesch S, Bürk K, Dürr A, Giunti P, Mariotti C, Pousset F, Schöls L, Vankan P, Pandolfo M.Diagnosis and treatment of Friedreich ataxia: a European perspectiveNat Rev Neurol . 2009 Apr;5(4):222-34. doi: 10.1038/nrneurol.2009.26
Swistel DG. Surgical myectomy for hypertrophic cardiomyopathy in the 21st century, the evolution of the "RPR" repair: resection, plication, and release / Swistel DG, Balaram SK. // Prog Cardiovasc Dis. 2012;54:498–502.
Swistel DG. The surgical management of obstructive hypertrophic cardiomyopathy: the RPR procedure — resection, plication, release / Swistel DG, Sherrid MV. // Ann Cardiothorac Surg. 2017;6(4):423–425.
Syed IS. Role of cardiac magnetic resonance imaging in the detection of cardiac amyloidosis / Syed IS, Glockner JF, Feng D et al. // JACC Cardiovasc Imaging. 2010;3:155–164.
Tariq M, Ware SM. Importance of genetic evaluation and testing in pediatric cardiomyopathy. World J Cardiol. 2014 Nov 26;6(11):1156-65.
Timmer, SA. Coronary microvascular function, myocardial metabolism, and energetics in hypertrophic cardiomyopathy: insights from positron emission tomography / Timmer SA, Knaapen P. // Eur Heart J Cardiovasc Imaging. 2013;14(2):95–101.
Topilsky Y. Left ventricular assist device therapy in patients with restrictive and hypertrophic cardiomyopathy / Topilsky Y, Pereira NL, Shah DK et al. // Circ Heart Fail. 2011;4:266–275.
Torres MF. Heart transplantation in patients with hypertrophic cardiomyopathy/ Torres MF, Perez-Villa F. // Glob Cardiol Sci Pract. 2018:32.
J.A. Towbin, W.J. McKenna, D.J. Abrams, M.J. Ackerman, H. Calkins, F.C.C. Darrieux, J.P. Daubert, C. de Chillou, et al. HRS expert consensus statement on evaluation, risk stratification, and management of arrhythmogenic cardiomyopathy. Heart Rhythm, 2019 Vol 16, No 11, 301-371.
Villa, AD. Microvascular ischemia in hypertrophic cardiomyopathy: new insights from high-resolution combined quantification of perfusion and late gadolinium enhancement / Villa AD, Sammut E, Zarinabad N et al. // J Cardiovasc Magn Reson. 2016; 18:4.
Wang W. Prognostic Implications of Nonsustained Ventricular Tachycardia in High-Risk Patients With Hypertrophic Cardiomyopathy / Wang W, Lian Z, Rowin EJ // Circ Arrhythm Electrophysiol. 2017;10(3):e004604.
Ware SM, Wilkinson JD, Tariq M, Schubert JA, Sridhar A, Colan SD. Genetic Causes of Cardiomyopathy in Children: First Results From the Pediatric Cardiomyopathy Genes Study. J Am Heart Assoc . 2021 May 4;10(9):e017731. doi: 10.1161/JAHA.120.017731
Ware SM. Genetics of paediatric cardiomyopathies. Curr Opin Pediatr. 2017 Oct;29(5):534-540.
Wasfy MM. Differentiating the athletes heart from hypertrophic cardiomyopathy / Wasfy MM, Weiner RB. // Current Opinion in Cardiology. 2015;30(5):500–505. 407. Watkins H. Inherited cardiomyopathies. / Watkins H, Ashrafian H, Redwood C. // N Engl J Med. 2011;364:1643–1656.
Weigner MJ. Risk for clinical thromboembolism associated with conversion to sinus rhythm in patients with atrial fibrillation lasting less than 48 hours / Weigner MJ, Caulfield TA, Danias PG et al. // AnnInternMed. 1997;126(8):615–620.
Weissler-Snir A. Prevention of sudden death in hypertrophic cardiomyopathy: bridging the gaps in knowledge / Weissler-Snir A, Adler A, Williams L et al. // Eur Heart J. 2017;38(22):1728–1737.
Weissler-Snir A. Usefulness of 14-day Holter for detection of nonsustained ventricular tachycardia in patients with hypertrophic cardiomyopathy / Weissler-Snir A, Chan RH, Adler A et al. // Am J Cardiol. 2016;118(8):1258–1263.
Whole-exome sequencing identifies rare compound heterozygous mutations in the MYBPC3 gene associated with severe familial hypertrophic cardiomyopathy // Eur J Med Genet. 2018;61(8):434–441.
Wilkinson JD, Lowe AM, Salbert BA, et al. Outcomes in children with Noonan syndrome and hypertrophic cardiomyopathy: a study from the Pediatric Cardiomyopathy Registry. Am Heart J. 2012;164(3):442–448.
Wolf C.M. Hypertrophic cardiomyopathy: genetics and clinical perspectives. Cardiovasc Diagn Ther . 2019 Oct;9(Suppl 2):S388-S415. doi: 10.21037/cdt.2019.02.01.
Yan LR. Clinical characteristics and prognosis of 60 patients with midventricular obstructive hypertrophic cardiomyopathy / Yan LR, Zhao SH, Wang HY et al. // J Cardiovasc Med (Hagerstown). 2015;16:51–60.
Yang Z. Danon disease as a cause of autophagic vacuolar myopathy / Yang Z, Vatta M. // Congenit Heart Dis. 2007;2:404–409.
Yang Z. Danon disease as an underrecognized cause of hypertrophic cardiomyopathy in children / Yang Z., McMahon CJ, Smith LR. // Circulation. 2005;112:1612–1617.
Zagatina A., Guseva O., Bartosh-Zelenaya S.Y.,Zhuravskaya N. Detection of ischemical dyssynchrony in patients with normal duration of QRS at rest and during exercise echocardiography (Dyssynchrony in coronary artery disease patients during exercise).Minerva Cardioangiol 2014; 62: 2: 161-176.
Ziolkowska L, Turska-Kmiec A, Petryka J, et al. Predictors of long-term outcome in children with hypertrophic cardiomyopathy. Pediatr Cardiol 2016; 37:448–458.